| Category | Key points | Evidence type (review/primary/bioinformatics) | Year | Source (first author, journal) | URL |
|---|---|---|---|---|---|
| Target identity | Human **P4HA3** matches UniProt **Q7Z4N8** and encodes **prolyl 4-hydroxylase subunit alpha-3**, the catalytic α(III) subunit of collagen prolyl 4-hydroxylase isoenzyme III; belongs to the P4HA family and is distinct from P4HA1/P4HA2 (pqac-00000006, pqac-00000007, pqac-00000009) | Review | 2017, 2021 | Gjaltema, *Crit Rev Biochem Mol Biol*; Salo, *Exp Dermatol* | https://doi.org/10.1080/10409238.2016.1269716 ; https://doi.org/10.1111/exd.14197 |
| Primary molecular function / reaction | Collagen prolyl 4-hydroxylases catalyze **4-hydroxylation of proline** to form **4-hydroxyproline (4Hyp)** in newly synthesized procollagen, a modification essential for triple-helix stability and efficient collagen secretion (pqac-00000007, pqac-00000009) | Review | 2017, 2021 | Gjaltema, *Crit Rev Biochem Mol Biol*; Salo, *Exp Dermatol* | https://doi.org/10.1080/10409238.2016.1269716 ; https://doi.org/10.1111/exd.14197 |
| Substrate specificity / motif | Minimum peptide requirement is **-X-Pro-Gly-**; hydroxylation occurs at the **Y-position of Gly-X-Y motifs** in collagen chains, and only on **unfolded procollagen α-chains** before triple-helix folding. For α(III)/P4HA3 specifically, substrate affinities remain less well defined than for P4HA1/2 (pqac-00000007, pqac-00000008, pqac-00000011) | Review | 2011, 2017 | Pasanen, thesis/review; Gjaltema, *Crit Rev Biochem Mol Biol* | https://doi.org/10.1080/10409238.2016.1269716 |
| Cofactors and byproducts | The reaction requires **Fe2+**, **2-oxoglutarate (2-OG/α-KG)**, **O2**, and **ascorbate**; 2-OG is oxidatively decarboxylated to **succinate + CO2**, with one oxygen atom incorporated into succinate and one into hydroxyproline (pqac-00000008, pqac-00000009) | Review | 2011, 2021 | Pasanen, thesis/review; Salo, *Exp Dermatol* | https://doi.org/10.1111/exd.14197 |
| Complex composition | Active collagen prolyl 4-hydroxylase is an **α2β2 tetramer**. P4HA3 supplies the catalytic **α(III)** subunit; the β-subunit is **P4HB/protein disulfide isomerase (PDI)**, required for α-subunit solubility, assembly, and chaperone function (pqac-00000006, pqac-00000007, pqac-00000009) | Review | 2011, 2017, 2021 | Pasanen; Gjaltema, *Crit Rev Biochem Mol Biol*; Salo, *Exp Dermatol* | https://doi.org/10.1080/10409238.2016.1269716 ; https://doi.org/10.1111/exd.14197 |
| Subcellular localization | Collagen P4Hs are localized in the **lumen of the rough endoplasmic reticulum (ER)**; ER retention is mediated by the **KDEL** signal on P4HB/PDI. This is the expected localization for P4HA3-containing isoenzyme III (pqac-00000006, pqac-00000007, pqac-00000009) | Review | 2011, 2017, 2021 | Pasanen; Gjaltema, *Crit Rev Biochem Mol Biol*; Salo, *Exp Dermatol* | https://doi.org/10.1080/10409238.2016.1269716 ; https://doi.org/10.1111/exd.14197 |
| Isoenzyme notes | Vertebrates express three α-subunit isoforms: **P4HA1/P4HA2/P4HA3 = α(I)/α(II)/α(III)**, forming isoenzymes I/II/III. Available evidence indicates α-subunits form **homomeric** tetramers rather than mixed α(I)/α(II)/α(III) complexes. **P4HA3 mRNA is generally lower-abundance** than P4HA1 and lacks reported alternative splicing in the cited sources (pqac-00000006, pqac-00000008, pqac-00000010, pqac-00000012) | Review | 2011, 2021, 2025 | Pasanen; Salo, *Exp Dermatol*; Hironaka, *Int J Mol Sci* | https://doi.org/10.1111/exd.14197 ; https://doi.org/10.3390/ijms26199371 |
| Biological role / pathway context | By enabling proline hydroxylation during collagen biosynthesis, P4HA3 contributes to **ECM assembly, collagen stability, and matrix remodeling**. In tumors, higher P4HA3 is repeatedly linked to **ECM stiffening/remodeling, EMT, invasion, metastasis, and tumor microenvironment changes** (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000005) | Review + primary/bioinformatics | 2021, 2023, 2024 | Shi, *Acta Biochim Biophys Sin*; Zhang, *Med Oncol*; Yu, *Sci Rep*; Huang, *PLoS Comput Biol* | https://doi.org/10.1093/abbs/gmab065 ; https://doi.org/10.1007/s12032-022-01926-2 ; https://doi.org/10.1038/s41598-024-73784-z ; https://doi.org/10.1371/journal.pcbi.1012284 |
| 2023 ccRCC finding | In **clear cell renal cell carcinoma**, P4HA3 was highly expressed in **TCGA KIRC (539 tumors)** and normal-adjacent comparison datasets; high expression associated with worse overall survival. Figure-based statistics reported **HR = 1.52, P = 0.007**; P4HA3 knockdown reduced proliferation, migration, and invasion in OSRC2 and 769-P cells, and GSEA implicated **EMT** and **PI3K/AKT/GSK3β** signaling (pqac-00000005, pqac-00000014) | Primary + bioinformatics | 2023 | Zhang, *Medical Oncology* | https://doi.org/10.1007/s12032-022-01926-2 |
| 2024 gastric cancer finding | In **gastric cancer**, elevated P4HA3 expression was reported as significantly associated with poorer prognosis and correlated with **immune infiltrating cells, immune markers, TMB, MSI, stromal/immune scores, and immune checkpoints**, supporting use as a candidate biomarker for prognosis and immunotherapy response; numeric effect sizes were not provided in the cited excerpt (pqac-00000002) | Primary + bioinformatics | 2024 | Yu, *Scientific Reports* | https://doi.org/10.1038/s41598-024-73784-z |
| 2024 pan-cancer / immunotherapy finding | A 2024 pan-cancer analysis across **33 tumor types** found P4HA3 expression associated with tumor-microenvironment infiltration, proliferation markers, and EMT markers; experimental depletion inhibited proliferation/migration/invasion and improved **PD-1/PD-L1 inhibitor** response in model systems, supporting P4HA3 as a possible immunotherapy-response biomarker (pqac-00000004) | Primary + bioinformatics | 2024 | Huang, *PLoS Comput Biol* | https://doi.org/10.1371/journal.pcbi.1012284 |
| 2024 head and neck cancer finding | In **head and neck squamous cell carcinoma**, P4HA1 and **P4HA3** were reported significantly higher in tumors than normal tissues; knockdown of collagen P4HA subunits reduced migration and invasion, and the study positioned LLGL2 as an antagonist of C-P4HA-driven aggressiveness. The paper also notes C-P4HA overexpression is prognostically adverse overall, though no P4HA3-specific hazard ratio was given in the cited excerpt (pqac-00000001) | Primary | 2024 | Xu, *Acta Biochim Biophys Sin* | https://doi.org/10.3724/abbs.2024140 |
| 2024 fibrosis-related evidence | P4HA3 is increasingly implicated in **fibrotic ECM programs**: spatial transcriptomic work in a fibrosis model highlighted dysregulated collagen prolyl hydroxylase activity including **P4HA3**, and TGFβ-driven human fibroblast transcriptomics identified **P4HA3** among collagen-synthesis/fibrosis-enriched genes. These support a role in profibrotic matrix remodeling, but quantitative P4HA3-specific effect sizes were not provided in the cited excerpts (pqac-00000000) | Database/association + primary transcriptomics | 2024 | Open Targets; Bell, *Cell Reports Medicine*; Pasvanis, *bioRxiv* | https://platform.opentargets.org ; https://doi.org/10.1016/j.xcrm.2024.101695 ; https://doi.org/10.1101/2024.03.09.583791 |
| Current limitations | Despite strong family-level biochemistry, **P4HA3-specific substrate preferences, kinetics, and non-collagen substrates remain incompletely characterized** relative to P4HA1/2. Several recent disease studies are largely correlative or bioinformatic, so mechanistic claims for P4HA3 should be interpreted cautiously unless supported by perturbation experiments (pqac-00000007, pqac-00000011, pqac-00000004, pqac-00000005) | Review + primary/bioinformatics | 2017, 2023, 2024 | Gjaltema, *Crit Rev Biochem Mol Biol*; Zhang, *Med Oncol*; Huang, *PLoS Comput Biol* | https://doi.org/10.1080/10409238.2016.1269716 ; https://doi.org/10.1007/s12032-022-01926-2 ; https://doi.org/10.1371/journal.pcbi.1012284 |


*Table: This table summarizes validated functional annotation facts for human P4HA3, including core collagen prolyl 4-hydroxylase biochemistry, localization, complex composition, and recent 2023-2024 disease-related findings. It is useful as a compact evidence map linking molecular function to current translational literature.*